Trading for the Elster Group has been strong in the ten months to October 2015 with sales up 14% versus last year at constant currency, 6% if excluding the acquisition of Eclipse in November last year. The sale of Elster to Honeywell announced on 28 July this year is on course to complete in the first quarter of 2016.
As previously announced Brush has been experiencing challenging end market conditions with the first half sales being down 26% at constant currency compared to last year. As expected, the performance has improved in the four months since the half year so that revenue for the ten months to October is down 17%. Trading is in line with expectations for the full year albeit potentially towards the lower end of the range.
Recent results from industrial companies globally have been somewhat downbeat and it may be that this trend continues for some time. In these uncertain circumstances, Melrose is optimistic that a suitable acquisition will be identified bringing with it another opportunity to create substantial value for shareholders.
-ends-
Enquiries:
Montfort Communications
Charlotte McMullen: +44 (0)7921 881 800
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.